<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985789</url>
  </required_header>
  <id_info>
    <org_study_id>PHPY2013/14</org_study_id>
    <nct_id>NCT01985789</nct_id>
  </id_info>
  <brief_title>Anti-histamines and Methacholine Challenges.</brief_title>
  <official_title>The Effect of Antihistamines on Methacholine Challenge Testing in Asthma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Don Cockcroft</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Saskatchewan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The asthmatic airway is identified and studied using inhaled agents such as histamine and
      methacholine. The use of antihistamines prior to the test will inhibit the test result if
      histamine is used to cause airway constriction. If using methacholine, this may also be true
      depending on whether old (e.g. benadryl) or new (e.g. desloratadine) antihistamines are used.
      This study will look at the effect of old and new antihistamines on inhaled methacholine
      challenge response in individuals with mild asthma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in methacholine pc20</measure>
    <time_frame>change from baseline (pre dose) at 2 hours (post dose)</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>diphenhydramine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg dose given as two 25mg capsules</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cetirizine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10mg dose given as 1 10mg capsule and 1 placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>desloratadine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5mg dose given as 1 5mg capsule and 1 placebo capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>given as 2 placebo capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine</intervention_name>
    <arm_group_label>diphenhydramine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cetirizine</intervention_name>
    <arm_group_label>cetirizine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>desloratadine</intervention_name>
    <arm_group_label>desloratadine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Baseline forced expiratory volume in 1s (FEV1) of 70% or more of predicted

          -  Methacholine provocative concentration causing a 20% fall in FEV1 16mg/ml or less

          -  No respiratory infection or change in allergen exposure for 4 weeks prior to screening
             and throughout the study

          -  No significant medical co-morbidities

          -  allergy

        Exclusion Criteria:

          -  pregnant or breastfeeding females

          -  unable to withhold antihistamines, anticholinergics, long acting bronchodilators and
             combination therapies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald W Cockcroft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Saskatchewan, Department of Medicine, Division of Respirology, Critical Care and Sleep Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Saskatchewan</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>April 7, 2015</last_update_submitted>
  <last_update_submitted_qc>April 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Saskatchewan</investigator_affiliation>
    <investigator_full_name>Don Cockcroft</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>airway hyperresponsiveness</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Desloratadine</mesh_term>
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Methacholine Chloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

